Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Ghrelin-induced hypothermia: a physiological basis but no clinical risk
Wiedmer P, Tschöp M, Joost H, Schürmann A, Lutz T, Dimarchi R, Blum D, Horvath T, Strasser F, Tong J. Ghrelin-induced hypothermia: a physiological basis but no clinical risk. Physiol Behav 2011; 105:43-51.
Apr 13, 2011Ghrelin-induced hypothermia: a physiological basis but no clinical risk
Apr 13, 2011Physiol Behav 2011; 105:43-51
Wiedmer Petra, Tschöp Matthias H, Joost Hans-Georg, Schürmann Annette, Lutz Thomas, Dimarchi Richard, Blum David, Horvath Tamas L, Strasser Florian, Tong Jenny
2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial
Bachner M, Cohn-Cedermark G, Daugaard G, Morelli F, Sella A, Harland S, Kerst M, Gampe J, Dittrich C, Fizazi K, Oldenburg J, Gillessen Sommer S, Loriot Y, Gross-Goupil M, Zucali P, Horwich A, Germa-Lluch J, Kollmannsberger C, Stoiber F, Fléchon A, Oechsle K, De Santis M. 2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol 2011; 23:59-64.
Apr 2, 20112-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial
Apr 2, 2011Ann Oncol 2011; 23:59-64
Bachner M, Cohn-Cedermark G, Daugaard G, Morelli F, Sella A, Harland S, Kerst M, Gampe J, Dittrich C, Fizazi K, Oldenburg J, Gillessen Sommer Silke, Loriot Y, Gross-Goupil M, Zucali P A, Horwich A, Germa-Lluch J-R, Kollmannsberger C, Stoiber F, Fléchon A, Oechsle K, De Santis M
Re-Irradiation with Bevacizumab in Recurrent Malignant Gliomas
Brügge D, Putora P, Hundsberger T, Weder P, van Leyen K, Plasswilm L (2011). Re-Irradiation with Bevacizumab in Recurrent Malignant Gliomas.
Mar 31, 2011Re-Irradiation with Bevacizumab in Recurrent Malignant Gliomas
Mar 31, 2011SASRO 2011
Brügge Detlef, Putora Paul Martin, Hundsberger Thomas, Weder Patrik, van Leyen Karin, Plasswilm Ludwig
Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03)
Köberle D, Thürlimann B, Pilop C, Crowe S, Öhlschlegel C, von Moos R, Zaman K, Pagani O, Jost L, Ruhstaller T, Swiss Group for Clinical Cancer Research (SAKK). Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03). Endocr Relat Cancer 2011; 18:257-64.
Mar 9, 2011Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03)
Mar 9, 2011Endocr Relat Cancer 2011; 18:257-64
Köberle Dieter, Thürlimann Beat, Pilop C, Crowe S, Öhlschlegel Christian, von Moos R, Zaman K, Pagani O, Jost L, Ruhstaller Thomas, Swiss Group for Clinical Cancer Research (SAKK)
Interdisciplinary evidence-based recommendations for the follow-up of early stage seminomatous testicular germ cell cancer patients
Souchon R, Hartmann M, Krege S, Lorch A, Mayer F, De Santis M, Gillessen Sommer S, Beyer J, Cathomas R. Interdisciplinary evidence-based recommendations for the follow-up of early stage seminomatous testicular germ cell cancer patients. Strahlenther Onkol 2011; 187:158-66.
Feb 21, 2011Interdisciplinary evidence-based recommendations for the follow-up of early stage seminomatous testicular germ cell cancer patients
Feb 21, 2011Strahlenther Onkol 2011; 187:158-66
Souchon Rainer, Hartmann Michael, Krege Susanne, Lorch Anja, Mayer Frank, De Santis Maria, Gillessen Sommer Silke, Beyer Jörg, Cathomas Richard
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial
Viale G, Thürlimann B, Mouridsen H, Mauriac L, Gelber R, Price K, Goldhirsch A, Gusterson B, Coates A, Láng I, Colleoni M, Regan M, Dell'orto P, Mastropasqua M, Maiorano E, Rasmussen B, Macgrogan G, Forbes J, Paridaens R, for the BIG 1-98 Collaborative and International Breast Cancer Study Groups. Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol 2011; 22:2201-2207.
Feb 18, 2011Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial
Feb 18, 2011Ann Oncol 2011; 22:2201-2207
Viale G, Thürlimann Beat, Mouridsen H, Mauriac L, Gelber R D, Price K N, Goldhirsch A, Gusterson B A, Coates A S, Láng I, Colleoni M, Regan M M, Dell'orto P, Mastropasqua M G, Maiorano E, Rasmussen B B, Macgrogan G, Forbes J F, Paridaens R J, for the BIG 1-98 Collaborative and International Breast Cancer Study Groups
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study
Colleoni M, Coates A, Gelber R, Price K, Wardley A, Pienkowski T, Chirgwin J, Smith I, Láng I, Paridaens R, Forbes J, Mauriac L, Mouridsen H, Thürlimann B, Regan M, Giobbie-Hurder A, Goldhirsch A. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol 2011; 29:1117-24.
Feb 14, 2011Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study
Feb 14, 2011J Clin Oncol 2011; 29:1117-24
Colleoni Marco, Coates Alan S, Gelber Richard D, Price Karen N, Wardley Andrew, Pienkowski Tadeusz, Chirgwin Jacquie, Smith Ian, Láng István, Paridaens Robert, Forbes John F, Mauriac Louis, Mouridsen Henning, Thürlimann Beat, Regan Meredith M, Giobbie-Hurder Anita, Goldhirsch Aron
Dose-toxicity models in oncology
Jörger M. Dose-toxicity models in oncology. Expert Opin Drug Metab Toxicol 2011; 7:201-11.
Feb 13, 2011Dose-toxicity models in oncology
Feb 13, 2011Expert Opin Drug Metab Toxicol 2011; 7:201-11
Jörger Markus
Transition to homozygosity does not appear to provide a clonal advantage to hematopoietic progenitors carrying mutations in TET2.
Schaub F, Lehmann T, Looser R, Hao-Shen H, Tichelli A, Skoda R. Transition to homozygosity does not appear to provide a clonal advantage to hematopoietic progenitors carrying mutations in TET2. Blood 2011; 117:2075-6.
Feb 10, 2011Transition to homozygosity does not appear to provide a clonal advantage to hematopoietic progenitors carrying mutations in TET2.
Feb 10, 2011Blood 2011; 117:2075-6
Schaub Franz X, Lehmann Thomas, Looser Renate, Hao-Shen Hui, Tichelli André, Skoda Radek C
Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer
Cima I, Wyler S, Zehetner J, Jochum W, Buhmann J, Cerny T, Moch H, Gillessen Sommer S, Aebersold R, Leippold T, Fuchs T, Schubert O, Schiess R, Wild P, Kaelin M, Schüffler P, Lange V, Picotti P, Ossola R, Templeton A, Krek W. Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer. Proc Natl Acad Sci USA 2011; 108:3342-7.
Feb 7, 2011Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer
Feb 7, 2011Proc Natl Acad Sci USA 2011; 108:3342-7
Cima Igor, Wyler Stephen, Zehetner Jens, Jochum Wolfram, Buhmann Joachim, Cerny Thomas, Moch Holger, Gillessen Sommer Silke, Aebersold Ruedi, Leippold Thomas, Fuchs Thomas, Schubert Olga, Schiess Ralph, Wild Peter, Kaelin Martin, Schüffler Peter, Lange Vinzenz, Picotti Paola, Ossola Reto, Templeton Arnoud, Krek Wilhelm
Dose-toxicity models in oncology
Adamina M, Jörger M. Dose-toxicity models in oncology. Expert Opin Drug Metab Toxicol 2011; 7:201-211.
Feb 1, 2011Dose-toxicity models in oncology
Feb 1, 2011Expert Opin Drug Metab Toxicol 2011; 7:201-211
Adamina Michel, Jörger Markus
Improving outcomes after laparoscopic appendectomy: a population-based, 12-year trend analysis of 7`446 patients
Brugger L, Rosella L, Candinas D, Gueller U. Improving outcomes after laparoscopic appendectomy: a population-based, 12-year trend analysis of 7`446 patients. Annals of surgery 2011; 253:309-313.
Feb 1, 2011Improving outcomes after laparoscopic appendectomy: a population-based, 12-year trend analysis of 7`446 patients
Feb 1, 2011Annals of surgery 2011; 253:309-313
Brugger L, Rosella L, Candinas D, Gueller Ulrich
Improving outcomes after laparoscopic appendectomy: a population-based, 12-year trend analysis of 7446 patients
Brügger L, Rosella L, Candinas D, Gueller U. Improving outcomes after laparoscopic appendectomy: a population-based, 12-year trend analysis of 7446 patients. Ann Surg 2011; 253:309-13.
Feb 1, 2011Improving outcomes after laparoscopic appendectomy: a population-based, 12-year trend analysis of 7446 patients
Feb 1, 2011Ann Surg 2011; 253:309-13
Brügger Lukas, Rosella Laura, Candinas Daniel, Gueller Ulrich
Negative appendicectomy and perforation rates in patients undergoing laparoscopic surgery for suspected appendicitis
Gueller U, Rosella L, McCall J, Brugger L, Candinas D. Negative appendicectomy and perforation rates in patients undergoing laparoscopic surgery for suspected appendicitis. Br J Surg 2011; 98:589-95.
Jan 24, 2011Negative appendicectomy and perforation rates in patients undergoing laparoscopic surgery for suspected appendicitis
Jan 24, 2011Br J Surg 2011; 98:589-95
Gueller Ulrich, Rosella L, McCall J, Brugger L E, Candinas D
[A Rare Cause of a Cervical Lymphadenopathy.]
Hinder R, Hitz F, Brugnolaro C, Stöckli S. [A Rare Cause of a Cervical Lymphadenopathy.]. Praxis (Bern 1994) 2011; 100:105-108.
Jan 19, 2011[A Rare Cause of a Cervical Lymphadenopathy.]
Jan 19, 2011Praxis (Bern 1994) 2011; 100:105-108
Hinder R, Hitz Felicitas, Brugnolaro C, Stöckli Sandro
Interdisciplinary evidence-based recommendations for the follow-up of testicular germ cell cancer patients
Cathomas R, Hartmann M, Krege S, Souchon R, Lorch A, Mayer F, De Santis M, Gillessen Sommer S, Interdisziplinäre Arbeitsgruppe Hodentumore. Interdisciplinary evidence-based recommendations for the follow-up of testicular germ cell cancer patients. Onkologie 2011; 34:59-64.
Jan 17, 2011Interdisciplinary evidence-based recommendations for the follow-up of testicular germ cell cancer patients
Jan 17, 2011Onkologie 2011; 34:59-64
Cathomas Richard, Hartmann Michael, Krege Susanne, Souchon Rainer, Lorch Anja, Mayer Frank, De Santis Maria, Gillessen Sommer Silke, Interdisziplinäre Arbeitsgruppe Hodentumore
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations.
Passamonti F, Elena C, Schnittger S, Skoda R, Green A, Girodon F, Kiladjian J, McMullin M, Ruggeri M, Besses C, Vannucchi A, Lippert E, Gisslinger H, Rumi E, Lehmann T, Ortmann C, Pietra D, Pascutto C, Haferlach T, Cazzola M. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood 2011; 117:2813-6.
Jan 11, 2011Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations.
Jan 11, 2011Blood 2011; 117:2813-6
Passamonti Francesco, Elena Chiara, Schnittger Susanne, Skoda Radek C, Green Anthony R, Girodon François, Kiladjian Jean-Jacques, McMullin Mary Frances, Ruggeri Marco, Besses Carles, Vannucchi Alessandro M, Lippert Eric, Gisslinger Heinz, Rumi Elisa, Lehmann Thomas, Ortmann Christina A, Pietra Daniela, Pascutto Cristiana, Haferlach Torsten, Cazzola Mario
Cancer cachexia: a systematic literature review of items and domains associated with involuntary weight loss in cancer
Blum D, Strasser F, Fearon K, Kaasa S, Stone P, Tan B, Solheim T, Baracos V, Omlin A, European Palliative Care Research Collaborative. Cancer cachexia: a systematic literature review of items and domains associated with involuntary weight loss in cancer. Crit Rev Oncol Hematol 2011; 80:114-44.
Jan 8, 2011Cancer cachexia: a systematic literature review of items and domains associated with involuntary weight loss in cancer
Jan 8, 2011Crit Rev Oncol Hematol 2011; 80:114-44
Blum David, Strasser Florian, Fearon Ken, Kaasa Stein, Stone Patrick, Tan Benjamin H L, Solheim Tora S, Baracos Vickie E, Omlin Aurelius, European Palliative Care Research Collaborative
Das Prostatakarzinom im Wandel. Grundpfeiler der Diagnostik, Behandlung und Interdisziplinarität
Cathomas R, Berthold D, Gillessen Sommer S, Recker F, Stenner F, Strebel R, Sulser T, Zwahlen D, Schmid H. Das Prostatakarzinom im Wandel. Grundpfeiler der Diagnostik, Behandlung und Interdisziplinarität. Schweiz Med Forum 2011; 11:759-63.
Jan 1, 2011Das Prostatakarzinom im Wandel. Grundpfeiler der Diagnostik, Behandlung und Interdisziplinarität
Jan 1, 2011Schweiz Med Forum 2011; 11:759-63
Cathomas R, Berthold D, Gillessen Sommer Silke, Recker F, Stenner F, Strebel RT, Sulser T, Zwahlen DR, Schmid Hans-Peter
Advances in Personalized Cancer Management
Früh M, Baty F, Putora P, Brutsche M. Advances in Personalized Cancer Management. In: Advances in Personalized Cancer Management. NovemberLondon: Future Medicine Ltd, 2011. ISBN 978-1-78084-068-0. pp. 58-67.
Jan 1, 2011Advances in Personalized Cancer Management
Jan 1, 2011Future Medicine Ltd, ISBN 978-1-78084-068-0
Früh Martin, Baty Florent, Putora Paul Martin, Brutsche Martin